Precision Pharmacotherapy Group

Publications 2019

Bergström M, Müller M, Karlsson M, Scholz H, Vethe NT, Korsgren O (2019)
Comparing the Effects of the mTOR Inhibitors Azithromycin and Rapamycin on In Vitro Expanded Regulatory T Cells
Cell Transplant, 963689719872488 (in press)
DOI 10.1177/0963689719872488, PubMed 31512504

Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O et al. (2019)
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Ther Drug Monit, 41 (3), 261-307
DOI 10.1097/FTD.0000000000000640, PubMed 31045868

Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KEA, Tveit KS, Lorentzen M, Berset IP, Fevang BTS, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G et al. (2019)
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
J Intern Med, 285 (6), 653-669
DOI 10.1111/joim.12880, PubMed 30762274

Gustavsen MT, Midtvedt K, Vethe NT, Robertsen I, Bergan S, Åsberg A (2019)
Tacrolimus area under the concentration versus time curve monitoring, using home-based volumetric absorptive capillary microsampling
Ther Drug Monit (in press)
DOI 10.1097/FTD.0000000000000697, PubMed 31479042

Klaasen RA, Egeland EJ, Chan J, Midtvedt K, Svensson M, Bolstad N, Fellström B, Holdaas H, Åsberg A, Bergan S, Vethe NT, Warren DJ (2019)
A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients
Ther Drug Monit, 41 (1), 11-18
DOI 10.1097/FTD.0000000000000580, PubMed 30633722

Kristiansen O, Vethe NT, Fagerland MW, Bergan S, Munkhaugen J, Husebye E (2019)
A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease
Br J Clin Pharmacol (in press)
DOI 10.1111/bcp.14122, PubMed 31495943

Munkhaugen J, Vethe NT, Fagerland MW, Dammen T, Perk J, Gjertsen E, Otterstad JE, Gullestad L, Bergan S, Husebye E (2019)
Statin-associated muscle symptoms in coronary patients: design of a randomized study
Scand Cardiovasc J, 53 (3), 162-168
DOI 10.1080/14017431.2019.1612085, PubMed 31030568

Tuv SS, Nordal K, Vethe NT, Bergan S (2019)
Pharmacogenetics in personalised drug therapy
Tidsskr Nor Laegeforen, 139 (8)
DOI 10.4045/tidsskr.19.0055, PubMed 31062549

Tuv SS, Vethe NT, Bergan S, Nordal K (2019)
Pharmacogenetics in personalised drug therapy
Tidsskr. Nor. Laegeforen., 139 (8), 700-702

Vethe NT, Munkhaugen J, Andersen AM, Husebye E, Bergan S (2019)
A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry
Ther Drug Monit, 41 (1), 19-28
DOI 10.1097/FTD.0000000000000578, PubMed 30633723

Publications 2018

Egeland EJ, Størset E, Robertsen I, Hermann M, Midtvedt K, Gustavsen MT, Klaasen R, Bergan S, Hartmann A, Åsberg A (2018)
The Authors' Reply
Transplantation, 102 (1), e43-e44
DOI 10.1097/TP.0000000000001961, PubMed 28957846

Eide IA, Reinholt FP, Jenssen T, Hartmann A, Schmidt EB, Åsberg A, Bergan S, Brabrand K, Svensson M (2018)
Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial
Am J Transplant, 19 (3), 790-800
DOI 10.1111/ajt.15080, PubMed 30125457

Heldal K, Midtvedt K, Hartmann A, Reisaeter AV, Heldal TF, Bergan S, Salvador CL, Åsberg A (2018)
Estimated glomerular filtration rate in stable older kidney transplant recipients-are present algorithms valid? A national cross-sectional cohort study
Transpl Int, 31 (6), 629-638
DOI 10.1111/tri.13137, PubMed 29453878

Klaasen RA, Bergan S, Bremer S, Daleq L, Andersen AM, Midtvedt K, Skauby MH, Vethe NT (2018)
Longitudinal Study of Tacrolimus in Lymphocytes During the First Year After Kidney Transplantation
Ther Drug Monit, 40 (5), 558-566
DOI 10.1097/FTD.0000000000000539, PubMed 30086087

Krogstad V, Vethe NT, Robertsen I, Hasvold G, Ose AD, Hermann M, Andersen AM, Chan J, Skauby M, Svensson MHS, Åsberg A, Christensen H (2018)
Determination of Tacrolimus Concentration and Protein Expression of P-Glycoprotein in Single Human Renal Core Biopsies
Ther Drug Monit, 40 (3), 292-300
DOI 10.1097/FTD.0000000000000510, PubMed 29578937

Munkhaugen J, Ruddox V, Halvorsen S, Dammen T, Fagerland MW, Hernæs KH, Vethe NT, Prescott E, Jensen SE, Rødevand O, Jortveit J, Bendz B, Schirmer H, Køber L, Bøtker HE, Larsen AI, Vikenes K, Steigen T, Wiseth R, Pedersen T, Edvardsen T, Otterstad JE, Atar D (2018)
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study
Am Heart J, 208, 37-46
DOI 10.1016/j.ahj.2018.10.005, PubMed 30530121

Publications 2017

Bremer S, Vethe NT, Skauby M, Kasbo M, Johansson ED, Midtvedt K, Bergan S (2017)
NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation
Br J Clin Pharmacol, 83 (11), 2494-2502
DOI 10.1111/bcp.13367, PubMed 28686294

Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Størset E, Gustavsen MT, Reisæter AV, Klaasen R, Bergan S, Holdaas H, Hartmann A, Åsberg A (2017)
High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation
Transplantation, 101 (8), e273-e279
DOI 10.1097/TP.0000000000001796, PubMed 28452920

Midtvedt K, Bergan S, Reisæter AV, Vikse BE, Åsberg A (2017)
Exposure to Mycophenolate and Fatherhood
Transplantation, 101 (7), e214-e217
DOI 10.1097/TP.0000000000001747, PubMed 28346297

Midtvedt K, Holdaas H, Bergan S, Åsberg A (2017)
Costimulation Blockade: America First, Canada Second … What About Norway?
Am J Transplant, 17 (8), 2230
DOI 10.1111/ajt.14351, PubMed 28508535

Olsen E, Bergan S, Mehl T, Burud I, Ekstrom KE, Di Sabatino M (2017)
Defect related radiative recombination in mono-like crystalline silicon wafers
Phys. Status Solidi A-Appl. Mat., 214 (8), 1700124

Salvador CL, Hartmann A, Åsberg A, Bergan S, Rowe AD, Mørkrid L (2017)
Estimating Glomerular Filtration Rate in Kidney Transplant Recipients: Comparing a Novel Equation With Commonly Used Equations in this Population
Transplant Direct, 3 (12), e332
DOI 10.1097/TXD.0000000000000742, PubMed 29536033

Skauby RH, Bjerre A, Sæves I, Vethe NT, Bremer S, Svarstad A, Bergan S (2017)
Prednisolone and Prednisone Pharmacokinetics in Pediatric Renal Transplant Recipients-A Prospective Study
Ther Drug Monit, 39 (5), 472-482
DOI 10.1097/FTD.0000000000000439, PubMed 28749817

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A (2017)
Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'
Br J Clin Pharmacol, 83 (6), 1357-1358
DOI 10.1111/bcp.13276, PubMed 28374426

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A (2017)
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation
Br J Clin Pharmacol, 83 (7), 1457-1465
DOI 10.1111/bcp.13248, PubMed 28146606

Publications 2016

Brunet M, Shipkova M, van Gelder T, Wieland E, Sommerer C, Budde K, Haufroid V, Christians U, López-Hoyos M, Barten MJ, Bergan S, Picard N, Millán López O, Marquet P, Hesselink DA, Noceti O, Pawinski T, Wallemacq P, Oellerich M (2016)
Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation
Ther Drug Monit, 38 Suppl 1, S1-20
DOI 10.1097/FTD.0000000000000287, PubMed 26977997

Kloster-Jensen K, Sahraoui A, Vethe NT, Korsgren O, Bergan S, Foss A, Scholz H (2016)
Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids
J Diabetes Res, 2016, 4196460
DOI 10.1155/2016/4196460, PubMed 26885529

Picard N, Bergan S, Marquet P, van Gelder T, Wallemacq P, Hesselink DA, Haufroid V (2016)
Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs
Ther Drug Monit, 38 Suppl 1, S57-69
DOI 10.1097/FTD.0000000000000255, PubMed 26469711

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A (2016)
Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance
Br J Clin Pharmacol, 83 (6), 1350-1352
DOI 10.1111/bcp.13188, PubMed 28008657

Størset E, von Düring ME, Godang K, Bergan S, Midtvedt K, Åsberg A (2016)
Prediction of Fat-Free Mass in Kidney Transplant Recipients
Ther Drug Monit, 38 (4), 439-46
DOI 10.1097/FTD.0000000000000305, PubMed 27019101

Størset E, Åsberg A, Hartmann A, Reisaeter AV, Holdaas H, Skauby M, Bergan S, Midtvedt K (2016)
Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience
Nephrology (Carlton), 21 (10), 821-7
DOI 10.1111/nep.12738, PubMed 26854648

Publications 2015

Bergan S, Bremer S, Vethe NT (2015)
Drug target molecules to guide immunosuppression
Clin Biochem, 49 (4-5), 411-8
DOI 10.1016/j.clinbiochem.2015.10.001, PubMed 26453533

Bremer S, Fløisand Y, Brinch L, Gedde-Dahl T, Bergan S (2015)
Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning
Ther Drug Monit, 37 (4), 493-500
DOI 10.1097/FTD.0000000000000180, PubMed 25565670

Cehajic I, Bergan S, Bjordal K (2015)
Pharmacist assessment of drug-related problems on an oncology ward
Eur. J. Hosp. Pharm.-Sci. Pract., 22 (4), 194-197

de Graav GN, Bergan S, Baan CC, Weimar W, van Gelder T, Hesselink DA (2015)
Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation
Ther Drug Monit, 37 (5), 560-7
DOI 10.1097/FTD.0000000000000179, PubMed 25551406

Karlsen Bjånes T, Mjåset Hjertø E, Lønne L, Aronsen L, Andsnes Berg J, Bergan S, Otto Berg-Hansen G, Bernard JP, Larsen Burns M, Toralf Fosen J, Frost J, Hilberg T, Krabseth HM, Kvan E, Narum S, Austgulen Westin A (2015)
Pharmacology Portal: An Open Database for Clinical Pharmacologic Laboratory Services
Clin Ther, 38 (1), 222-6
DOI 10.1016/j.clinthera.2015.10.015, PubMed 26546404

Kloster-Jensen K, Vethe NT, Bremer S, Abadpour S, Korsgren O, Foss A, Bergan S, Scholz H (2015)
Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro
Transpl Int, 28 (10), 1152-61
DOI 10.1111/tri.12617, PubMed 26046470

Robertsen I, Vethe NT, Midtvedt K, Falck P, Christensen H, Åsberg A (2015)
Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations
Ther Drug Monit, 37 (5), 675-80
DOI 10.1097/FTD.0000000000000185, PubMed 25565673

Robertsen I, Åsberg A, Ingerø AO, Vethe NT, Bremer S, Bergan S, Midtvedt K (2015)
Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed
Transplantation, 99 (3), 528-32
DOI 10.1097/TP.0000000000000384, PubMed 25148382

Salvador CL, Tøndel C, Mørkrid L, Bjerre A, Brun A, Bolann B, Brackman D, Bergan S (2015)
Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots
Scand J Clin Lab Invest, 75 (8), 710-6
DOI 10.3109/00365513.2015.1091091, PubMed 26426851

Størset E, Åsberg A, Skauby M, Neely M, Bergan S, Bremer S, Midtvedt K (2015)
Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study
Transplantation, 99 (10), 2158-66
DOI 10.1097/TP.0000000000000708, PubMed 25886918

 

 
Page visits: 692